U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Omadacycline Injection and Oral Products
  1. Development Resources

Omadacycline Injection and Oral Products

FDA Identified Interpretive Criteria

For Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion (zone
diameters in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae a,†

≤4

8

≥ 16

≥18

16-17

≤15

Staphylococcus aureus (including
methicillin‑resistant isolates)

≤ 0.5

1.0

≥ 2.0

≥ 21

19-20

≤18

Staphylococcus lugdunensis

≤ 0.12

0.25

≥0.5

≥ 29

26-28

≤25

Enterococcus faecalis

≤ 0.25

0.5

≥ 1.0

≥18

16-17

≤15

Streptococcus anginosus group b 

≤ 0.12

0.25

≥ 0.5

≥ 24

18-23

≤17

Streptococcus pyogenes

≤ 0.12

0.25

≥ 0.5

≥19

16-18

≤15

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 30 mcg omadacycline

Omadacycline is not active in vitro against Morganella spp., Proteus spp., and Providencia spp.

a Klebsiella pneumoniae and Enterobacter cloacae only

b Streptococcus anginosus group includes S. anginosus, S. intermedius, and S. constellatus

For Community Acquired Bacterial Pneumonia (CABP)

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion (zone
diameters in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae a,†

≤4

8

≥ 16

≥18

16-17

≤15

Staphylococcus aureus (methicillin- susceptible isolates only)

≤ 0.25

0.5

≥ 1.0

≥ 23

21-22

≤20

Haemophilus species b

≤2

4

≥ 8

≥ 20

17-19

≤16

Streptococcus pneumoniae

≤0.12

0.25

≥ 0.5

≥20

17-19

≤16

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 30 mcg omadacycline

Omadacycline is not active in vitro against Morganella spp., Proteus spp., and Providencia spp.

a Klebsiella pneumoniae only

b Haemophilus species includes H. influenzae and H. parainfluenzae